The global pharmaceutical industry historically has been significantly influenced by the US market, and the newly elected President Trump is anticipated to have a substantial impact on the industry in 2025.
The 47th President has indicated a markedly different approach in his second term, raising questions about the effects on medicine regulation, policies, pricing in the US as well as potential global impact. The implications for the pharmaceutical industry, particularly in Ireland, will be discussed at this event alongside our guest speaker Paul Sweetman, CEO of the American Chamber of Commerce in Ireland.
Paul Sweetman, CEO – American Chamber of Commerce, Ireland
Paul is CEO of the American Chamber of Commerce Ireland. He leads AmCham to ensure Ireland is a location where US FDI thrives, alongside supporting the growth of Irish companies as they expand in the US.
Paul joined AmCham from the public affairs consultancy Instinctif Partners, where he was Managing Partner. Prior to this, Paul worked with Ibec, holding numerous roles including Director of Financial Services Ireland, Director of Technology Ireland, Head of Transport & Public-Private Partnership Policy, and Environment Policy Executive. He is a Chartered Engineer with a bachelor’s in engineering from UCD and a master’s in environmental engineering from Virginia Tech, USA.
Please note that by registering for this event you agree to share your name and company details with the organisers and the event sponsor.
